ClinicalTrials.gg
Active, not recruitingNCT07737717Updated Sep 24, 2026

A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants

A Phase 1 interventional study of mRNA-1469 and Placebo in Ebola-Bundibugyo Virus Disease (Ebola-BDBV), sponsored by ModernaTX, Inc.. Active, not recruiting at 3 sites in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main objective of this trial is to evaluate the safety and reactogenicity of mRNA-1469

02

Conditions studied

  • Ebola-Bundibugyo Virus Disease (Ebola-BDBV)

Keywords

  • Ebola-Bundibugyo Virus Disease (Ebola-BDBV)
  • Moderna
  • Healthy Participants
03

In context

Lead sponsor

ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.

Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • In good general health or with stable chronic medical conditions, as determined by medical evaluation including medical history, physical examination, and laboratory tests.
  • within the range 18.5 to 39 kg/m2 (inclusive).
  • Female participants of may be enrolled in the study if not pregnant or breastfeeding, subject to other criteria specified in the study protocol.

Key Exclusion Criteria:

  • History of anaphylaxis or severe reaction requiring medical intervention after receipt of any mRNA vaccine or therapeutic, or any components of an mRNA vaccine or therapeutic.
  • History of participation in a prior vaccine study for pathogens causing Ebola virus disease.
  • History of confirmed or suspected filovirus exposure or infection or travel to an impacted area within 1 month prior to the Screening Visit (e.g. Ebola Zaire, Sudan, BDBV, and Marburg).
  • Other conditions that in the Investigator's opinion could interfere with interpretation of study results or limit the participant's participation in the study.
  • Acutely ill or febrile (temperature ≥38.0℃ [100.4°F]) within 72 hours prior to or at the Screening Visit or Day 1.
  • Abnormal screening clinical laboratory values >Grade 1 for total white blood cell count, , , aspartate aminotransferase, creatinine, alkaline phosphatase, total , or .
  • History of a diagnosis or condition that, in the judgment of the Investigator, is clinically unstable, potentially affects participant safety, the assessment of study endpoints, the assessment of immune response, or adherence to study procedures.

Note: Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    mRNA-1469 Dose Level 1

    Participants will receive 1 injection of mRNA-1469 at Dose Level 1 on Day 1.

    Biological: mRNA-1469

  • Placebo comparator
    Placebo Matching Dose Level 1

    Participants will receive 1 injection of Placebo matching Dose Level 1 on Day 1.

    Biological: Placebo

  • Experimental
    mRNA-1469 Dose Level 2

    Participants will receive 1 injection of mRNA-1469 at Dose Level 2 on Day 1.

    Biological: mRNA-1469

  • Placebo comparator
    Placebo Matching Dose Level 2

    Participants will receive 1 injection of Placebo matching Dose Level 2 on Day 1.

    Biological: Placebo

  • Experimental
    mRNA-1469 Dose Level 3

    Participants will receive 1 injection of mRNA-1469 at Dose Level 3 on Day 1.

    Biological: mRNA-1469

  • Placebo comparator
    Placebo Matching Dose Level 3

    Participants will receive 1 injection of Placebo matching Dose Level 3 on Day 1.

    Biological: Placebo

Interventions

  • BiologicalmRNA-1469

    Sterile liquid for injection

  • BiologicalPlacebo

    Sterile liquid for injection

06

What researchers measure

Primary outcomes

  1. Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)

    Time frame: Up to Day 7 (the day of study intervention and 6 subsequent days)

  2. Number of Participants with Unsolicited Adverse Events (AEs)

    Time frame: Up to Day 28 (the day of study intervention and 27 subsequent days)

  3. Number of Participants with Medically Attended Adverse Events (MAAEs)

    Time frame: Up to Day 169 (6 months follow-up after injection)

  4. Number of Participants with Serious Adverse Events (SAEs), Any AEs Leading to Discontinuation From Study Participation and/or Study Vaccination, and AEs of Special Interest (AESIs)

    Time frame: Up to End of Study (EOS) (Day 337)

Secondary outcomes

  1. Geometric Mean of Bundibugyo Ebolavirus (BDBV)-Specific Binding Antibodies (bAbs)

    Time frame: At Day 29 and Up to Day 337

07

Study locations

3 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Sep 2027, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2026
First posted
Jul 30, 2026
StartActual
Jul 31, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07737717
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Jul 30, 2026
Start date
Jul 31, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Sep 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion